ASH: Gilead­'s Kite un­veils more da­ta on Yescar­ta's win in sec­ond-line lym­phoma pa­tients, set­ting up bat­tle for SOC

As a spate of re­searchers work dili­gent­ly on next-gen CAR-T cell ther­a­pies, the big play­ers in the cur­rent gen­er­a­tion of those drugs are still an­gling for more mar­ket share. Get­ting to pa­tients ear­li­er is now the game plan, and Gilead’s Kite has un­corked some im­pres­sive da­ta back­ing up its case in lym­phoma.

Kite’s Yescar­ta (axi­cab­ta­gene ciloleu­cel) cut the risk of dis­ease pro­gres­sion, death or the need for ad­di­tion­al ther­a­py by a lit­tle more than 60% com­pared with stan­dard of care in sec­ond-line pa­tients with re­lapsed or re­frac­to­ry large B cell lym­phoma, ac­cord­ing to full da­ta from the Phase III ZU­MA-7 study re­vealed Sat­ur­day at #ASH21.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER